KUMAR, RAVINDRA,VENKATA SAI RAJASEKHAR SURAGANI, NAGA
申请号：
CA3031909
公开号：
CA3031909A1
申请日:
2017.07.26
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
In part, the present disclosure relates methods for treating, preventing, or reducing the progression rate and/or severity of myelofibrosis or one or more complications of myelofibrosis (extramedullary hematopoiesis, splenomegaly, anemia, and fibrosis). In certain aspects, the disclosure provides ActRIIB antagonists for use in treating, preventing, or reducing the progression rate and/or severity of one or more complications associated with Janus kinase inhibitor therapy in a patient (e.g., anemia).
